Navigation Links
Genzyme Launches Cholestagel(R) in Europe
Date:10/23/2007

rolemia (FH) -- an inherited disorder that causes exceptionally high levels of LDL-cholesterol -- who cannot reach their target LDL- cholesterol levels with a maximum regimen of statins and ezetimibe alone.

This double-blind, randomized "TRIPLE" study will involve 80 patients with FH enrolled in six European centers (including in the UK, Netherlands, Sweden and France) and preliminary results are expected in Q3 2008.

"Patients with genetic conditions like familial hypercholesterolemia are at particularly high risk of early coronary heart disease," said Dr. Anthony Wierzbicki, from London's St. Thomas' Hospital and a board member and chairman of the Medical Scientific and Research Committee of FH patient association 'Heart UK'. "Patients have to take multiple cholesterol-lowering therapies and yet still often require further cholesterol reduction to reach target lipid levels recommended for patients at risk of cardiovascular events. New non-systemic agents are a welcome addition for these patients to help them achieve these targets."

Unlike most other cholesterol-lowering treatments, Cholestagel is non- systemic, and therefore is not absorbed into the bloodstream. Cholestagel binds bile acids in the intestine, impeding their reabsorption. This process -- called bile acid sequestration -- results in an increased clearance of LDL cholesterol from the blood. Cholestagel is also well tolerated, with minimal gastrointestinal side effects similar to those seen in placebo, and has limited drug-interaction.

Colesevelam has been approved for use in the United States since 2000, where it is marketed by Daiichi Sankyo Inc. under the trade name WelChol(R). Genzyme plans to launch Cholestagel in the United Kingdom, the Netherlands and the Scandinavian region this quarter, and in additional European countries next year. Genzyme also intends to pursue regulatory approvals for Cholestagel in Latin America, Canada, and the Asia Pacific region.

Genzyme ha
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. Merge launches diagnostic mammography workstation in Europe
5. Einstein Wireless launches cellular alert system
6. Logistics Health launches compliance management tool
7. UW-Madison launches new high-speed research network
8. UWM launches research foundation
9. TeraMedica launches information manager
10. GE Healthcare launches hybrid electronic record
11. Cedara launches new version of DICOM toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... a biopharmaceutical company advancing patient care in critical areas, ... 3,500,000 shares of common stock, and warrants to purchase ... at an offering price of $4.00 per share and ... exercise price of $5.00, are exercisable immediately, and expire ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... and targeting Swiss biotechnology company, Syngenta, are in the ... for pretrial proceedings. The consolidated case is In Re: ... in the U.S. District Court for the District of ... litigation (MDL) has been handed over to U.S. District ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ... negative is the housing market remaining soft. , This solid ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... , PHILADELPHIA, June 3 Waters Corporation (NYSE: ... American Society for Mass Spectrometry (ASMS) presented Prof. ... the first Ron Hites Award for Outstanding Research ... of Mass Spectrometry (JASMS). Prof. Ashcroft,s paper titled, ...
... , Sees opportunity to end abusive use of authorized ... June 3 Mylan Inc.,s (Nasdaq: MYL ... the U.S. House of Representatives Judiciary Subcommittee on Courts ... pharmaceutical companies and generic pharmaceutical companies. During her testimony, ...
... 3 The Gamida Cell-Teva Joint Venture,announced today that five prestigious ... Valencia, have joined the Excel study. , , ... Hospital Clinic of Barcelona, Barcelona, Principal Investigator, Dr. ... Valencia, Valencia, Principal Investigator, Dr. Cristina Arbona, MD, ...
Cached Biology Technology:First ASMS Hites Award for Outstanding Research Publication Presented to Prof. Alison Ashcroft for Her Use of Waters Synapt HDMS System to Explore Protein Complexes 2First ASMS Hites Award for Outstanding Research Publication Presented to Prof. Alison Ashcroft for Her Use of Waters Synapt HDMS System to Explore Protein Complexes 3Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 3
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... Head, SCReactive oxygen species (ROS) occur as a ... by damaging proteins, nucleotides and lipids. Organisms ... the effects of ROS, and the oxidative stress ... performance declines with age due to lifetime accrual ...
... was launched simultaneously by Global Carbon Project co-chair Michael ... the USA at Capitol Hill, Washington by GCP Executive ... posted the most recent figures for the worlds, carbon ... added to the atmosphere, the underpinning of human induced ...
... Sept. 24, 2008 Calorie restriction, a diet that is ... as effective at extending life in people as it is ... Medicine in St. Louis. Previous research had shown ... food can live up to 50 percent longer. Because of ...
Cached Biology News:Researchers discover that growing up too fast may mean dying young in honey bees 2Researchers discover that growing up too fast may mean dying young in honey bees 3Growth in the global carbon budget 2Researchers note differences between people and animals on calorie restriction 2Researchers note differences between people and animals on calorie restriction 3
Request Info...
... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
... 1 kit. Convenient way to ... Conjugations are carried out under mild conditions ... Dyes are packaged in premeasured amounts and ... Category: Blotting & Labeling & Detection, Protein ...
...
Biology Products: